Thoracic Radiotherapy for Renal Cell Carcinoma Metastases: Local Control for the Management of Lung and Mediastinal Disease in the Modern Era

Stewart, Glenn; Breen, William; Stish, Bradley J.; Mullikin, T.C.; Park, Sean S.; Olivier, Kenneth R.; Costello, Brian A.

doi:10.1016/j.clgc.2021.11.001

Cited by 5 publications

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[64] Further, Stewart et al have identified radiation therapy as a viable method for managing the prevalent incidence of LM-RCC, effectively addressing lesions that constitute significant mortality threats. [65] Contrarily, Gonnet et al present radiofrequency ablation (RFA) as a secure and efficacious surgical substitute within an integrated systemic treatment strategy, with patients undergoing RFA for LM-RCC exhibiting favorable OS and prolonged systemic treatment-free survival. [60] Consequently, resection of metastatic pulmonary lesions, especially when a complete resection is viable, continues to be the foundational approach in the treatment of LM-RCC.…”

Section: Lung Metastasis From Rcc (Lm-rcc)mentioning

confidence: 99%

Therapeutic options for different metastatic sites arising from renal cell carcinoma: A review

Wang,

Qian,

Qian

et al. 2024

Medicine

View full text Add to dashboard Cite

Renal cell carcinoma (RCC) stands among the top 10 malignant neoplasms with the highest fatality rates. It exhibits pronounced heterogeneity and robust metastatic behavior. Patients with RCC may present with solitary or multiple metastatic lesions at various anatomical sites, and their prognoses are contingent upon the site of metastasis. When deliberating the optimal therapeutic approach for a patient, thorough evaluation of significant risk factors such as the feasibility of complete resection, the presence of oligometastases, and the patient’s functional and physical condition is imperative. Recognizing the nuanced differences in RCC metastasis to distinct organs proves advantageous in contemplating potential treatment modalities aimed at optimizing survival outcomes. Moreover, discerning the metastatic site holds promise for enhancing risk stratification in individuals with metastatic RCC. This review summarizes the recent data pertaining to the current status of different RCC metastatic sites and elucidates their role in informing clinical management strategies across diverse metastatic locales of RCC.

show abstract

Section: Lung Metastasis From Rcc (Lm-rcc)mentioning

confidence: 99%

Therapeutic options for different metastatic sites arising from renal cell carcinoma: A review

Wang,

Qian,

Qian

et al. 2024

Medicine

View full text Add to dashboard Cite

show abstract

“…In another single center study, Stewart et al [18] reviewed 71 mRCC patients specifically with lung and mediastinal RCC metastases treated with SRT at their institution. The primary endpoint of the study was local disease control.…”

Section: Stereotactic Radiotherapymentioning

confidence: 99%

Metastasis-directed treatment in kidney cancer

Jackson

Franco

Wang

et al. 2023

Current Opinion in Urology

View full text Add to dashboard Cite

Purpose of review To provide a critical overview of the latest evidence on the role of metastasis-direct treatment (MDT) in the management of metastatic renal cell carcinoma (mRCC). Recent findings This is a nonsystematic review of the English language literature published since January 2021. A PubMed/MEDLINE search using various search terms was conducted, including only original studies. After title and abstract screening, selected articles were grouped into two main areas which mirror the main treatment options in this setting: surgical metastasectomy (MS) and stereotactic radiotherapy (SRT). While a limited number of retrospective studies have been reported on surgical MS, the consensus of these reports is that extirpation of metastasis should be part of a multimodal management strategy for carefully selected cases. In contrast, there have been both retrospective studies and a small number of prospective studies on the use of SRT of metastatic sites. Summary As the management of mRCC rapidly evolves, and evidence on MDT – both in the form of MS and SRT – has continued to build over the past 2 years. Overall, there is growing interest in this therapeutic option, which is increasingly being implemented and seems to be safe and potentially beneficial in well selected disease scenarios.

show abstract

Antineoplastics

2022

Reactions Weekly

View full text Add to dashboard Cite

Thoracic Radiotherapy for Renal Cell Carcinoma Metastases: Local Control for the Management of Lung and Mediastinal Disease in the Modern Era

Cited by 5 publications

References 15 publications

Therapeutic options for different metastatic sites arising from renal cell carcinoma: A review

Therapeutic options for different metastatic sites arising from renal cell carcinoma: A review

Metastasis-directed treatment in kidney cancer

Antineoplastics

Contact Info

Product

Resources

About